Je was op zoek naar: sclc (Deens - Engels)

recidiverende sclc
relapsed sclc

oversigt over overlevelse, responsrate og tiden indtil progression hos patienter med sclc, der blev behandlet med oral topotecan eller intravenøs topotecan
summary of survival, response rate, and time to progression in sclc patients treated with oral topotecan or intravenous topotecan

i begge studier medførte oral og intravenøs topotecan samme symptomlindring hos patienter med recidiverende, sensitiv sclc i henhold til patienternes egne rapporteringer på en ublindet symptomskala.
oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive sclc in patient self- reports on an unblinded symptom scale assessment in each of these two studies.

oversigt over overlevelse, responsrate og tiden indtil progression hos sclc- patienter, der er behandlet med oral hycamtin eller intravenøs hycamtin
summary of survival, response rate, and time to progression in sclc patients treated with oral hycamtin or intravenous hycamtin

i patienternes egne rapporteringer vha. en ublindet vurdering på en symptomskala i begge forsøg, var oral og iv topotecan forbundet med samme symptomlindring hos patienter med recidiverende, sensitiv sclc.
oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive sclc in patient self- reports on an unblinded symptom scale assessment in each of these two studies.

sikkerhedsdata præsenteres ud fra et integreret datagrundlag med 682 patienter med recidiverende lungecancer, som havde fået 2.536 behandlingsperioder med oral topotecan-monoterapi (275 patienter med recidiverende sclc og 407 med recidiverende non-sclc).
safety data are presented based on an integrated data set of 682 patients with relapsed lung cancer administered 2536 courses of oral topotecan monotherapy (275 patients with relapsed sclc and 407 with relapsed non-sclc).